French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ICT01 selectively activates circulating γ9δ2 T cells that leads to migration of γ9δ2 T cells out of the circulation and into target tissue (e.g., tumors or infection site), ...

Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and encouraging clinical activity for ICT01 monotherapy in relapsed/refractory ...

Two clinical trials are underway to test ICT01: Eviction is testing the drug alone and in combination with Merck's Keytruda. Eviction-2 is testing the drug with an IL-2 inhibitor.

Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION ...

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023Interim data from ...

ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...